Patient Parameters
9 – 60 mmHg
mmHg
For NTG, untreated IOP is typically ≤21 mmHg. If higher, consider POAG or verify context.
6 – 60 mmHg
mmHg
Target IOP Range
—
mmHg
OK
Within target
  • Disc hemorrhage at any visit
  • Structural or functional progression despite IOP in target
  • Central visual field threat or fixation involvement
  • Young patient or long life expectancy
  • Monophthalmic patient
  • Significant vascular risk factors
Share feedback or report a case

Evidence-informed starting range for clinical guidance only. Does not replace specialist judgment or individualized assessment.

Input IOP values should be Goldmann-measured. Enter the original measured value; no numerical pachymetry correction is applied. CCT is incorporated as a categorical clinical modifier. For separate IOP/CCT contextualisation, use M1.

Eyes with extreme CCT (<480 µm or >620 µm) may require additional clinical judgement.

This tool estimates a suggested target IOP range based on glaucoma stage, central corneal thickness (CCT), and progression status. It applies guideline-derived target bands for open-angle glaucoma — including normal-tension glaucoma — and ocular hypertension, and has not been validated for angle-closure or secondary glaucomas.

When untreated baseline IOP is unavailable, the displayed range is a stage-based starting reference rather than an individualized target. It should be refined using baseline and longitudinal clinical data.

The suggested range is a starting point, not a fixed prescription. Target IOP must be reassessed over time according to treatment response, structural or functional progression, optic nerve findings, and patient-specific factors.

CCT is incorporated as a categorical clinical modifier (thin, average, or thick) that biases the result toward the lower or upper portion of the recommended band. It does not represent a numerical correction of measured IOP. The original Goldmann-measured IOP, not an M1-derived estimate or other CCT-adjusted value, should be entered in M2. Individual corneal biomechanical properties are not accounted for in this model.

For ocular hypertension, borderline untreated IOP values are interpreted together with CCT using predefined clinical compatibility rules. This categorical approach reflects the possible direction of tonometric bias but is not a numerical IOP correction or a definitive diagnostic criterion. When the entered baseline IOP and CCT combination falls outside the supported pathway, no target range is generated and clinical reassessment is required.

The clinician retains full responsibility for diagnostic and therapeutic decisions. This tool is intended as a decision-support aid and is not a substitute for clinical evaluation. Not intended for patient self-use.

  • Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128(1S):P71–P150.
  • European Glaucoma Society. Terminology and guidelines for glaucoma, 6th edition. Br J Ophthalmol. 2025;109(Suppl 1):1–72.
  • Weinreb RN, Khaw PT. Primary open-angle glaucoma: target intraocular pressure. Surv Ophthalmol. 2004;49(5):529–545.
  • Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495–505.
  • Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
  • v1.1Jul 2026
    • Mode B wording clarified when baseline IOP is unavailable
    • Disclaimer expanded for stage-based reference use, CCT input handling, and OHT compatibility rules
    • OHT progression hint clarified
    • Incorrect Sihota reference attribution corrected
    • Copied result now reports the estimation mode
    • Stored results are invalidated when inputs change, reset occurs, or calculation is withheld
    • No change to clinical logic, target ranges, thresholds, or algorithm v1.0.0
  • v1.0Mar 2026
    • Initial public release
    • Target IOP estimation — Mode A (personalized) and Mode B (stage-based)
    • OHT, NTG, Mild, Moderate, and Severe POAG supported
    • CCT-modulated targets aligned to published clinical evidence
    • Input validation, clinical flags, and gap row across all categories